Mode
Text Size
Log in / Sign up
Phase 3 Completed N=115 Randomized Treatment

Comparison of Recovery From Rocuronium 1.2 mg/kg Followed by Sugammadex (Org 25969) 16 mg/kg at 3 Minutes With Recovery From Succinylcholine 1.0 mg/kg (19.4.303)(P05946)(MK-8616-026)

Anesthesia, General
Source: ClinicalTrials.gov NCT00474253 ↗
Enrolled (actual)
115
Serious AEs
0.9%
Results posted
Mar 2019
Primary outcomePrimary: Time to Recovery of T1 to 10% of Baseline Value From Start of Rocuronium + Sugammadex or Succinylcholine Administration — 4.35; 7.15 Minutes
◆ Published Evidence
Highly cited
242citations · ~14 / year
Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine.
Anesthesiology · 2009 · Open access · Likely link

Summary

The purpose of the trial is to demonstrate a faster recovery from neuromuscular block induced by 1.2 mg/kg rocuronium after reversal at 3 minutes by 16.0 mg/kg of sugammadex compared with recovery after a neuromuscular block induced by 1.0 mg/kg succinylcholine.

Linked Publications

  • Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine.
    Anesthesiology · 2009 · 242 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Time to Recovery of T1 to 10% of Baseline Value From Start of Rocuronium + Sugammadex or Succinylcholine Administration
4.35; 7.15
SECONDARY
Time to Recovery of T1 to 90% of Baseline Value From Start of Rocuronium + Sugammadex or Succinylcholine Administration
6.13; 11.03
SECONDARY
Level of Consciousness: Number of Participants Awake and Oriented
8; 13; 19; 33
SECONDARY
Level of Consciousness: Number of Participants Arousable With Minimal Stimulation
7; 15; 1; 2
SECONDARY
Level of Consciousness: Number of Participants Responsive Only to Tactile Stimulation
5; 7; 0; 0
SECONDARY
Number of Participants Able to Perform 5-Second Head Lift
13; 24; 20; 35
SECONDARY
Number of Participants Experiencing General Muscle Weakness
2; 3; 0; 0

Eligibility Criteria

Inclusion Criteria

  • American Society of Anesthesiologists (ASA) Class 1 or 2 physical status;
  • 18 to 65 years of age (inclusive);
  • Scheduled for elective surgical procedure under general anesthesia requiring a short duration of neuromuscular block with the use of rocuronium or succinylcholine and requiring endotracheal intubation;
  • Scheduled for surgery in supine position;
  • Body mass index (BMI) 6 months), IUD, abstinence];
  • Has already participated in a sugammadex trial including Protocol 19.4.303.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00474253) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search